ESPE Yearbook of Paediatric Endocrinology

To read the full abstract: Pediatr Diabetes. 2018 19(5):1007-1013Severe hypoglycemia is one of the most threatening events in management of diabetes for parents and relatives. Although parents and patients are taught about the management in the acute situation, many are unable to use injectable glucagon. For moderate hypoglycemia, injectable glucagon seems to be no alternative for most caregivers. N...

Brief Summary: This double-blind, placebo-controlled international trial, randomized overweight and obese adults with T2D to either once-weekly subcutaneous Tirzepatide (10 mg or 15 mg) or placebo for 72 weeks. Tirzepatide led to weight reductions of -9.6% with the 10 mg dose and -11.6% with the 15 mg dose, compared to placebo. From a mean baseline 8.0%, HbA1c reduced by –2·1% with both the 10 mg, and 15 mg dose of triszepatied compared to 0·5% reduction on plac...